Wed.Dec 06, 2023

article thumbnail

FDA Approves Iptacopan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Adult Patients

Pharmacy Times

During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.

FDA 153
article thumbnail

New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility

STAT

As a teenager, Marie Tornyenu was always having to explain herself. If it wasn’t the chronic absences that had her doing homework from a hospital bed, it was the quilted blanket she carried with her on the days she could attend class. “It was a running joke that I was like 80 years old,” she said. “I would usually just laugh it off because the alternative was too depressing.

Hospitals 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HIV/AIDS Awareness Month Highlights Opportunities for Pharmacy

Pharmacy Times

As HIV has become a manageable chronic condition, and even curable in some cases, the role of pharmacists cannot be understated.

145
145
article thumbnail

New England Journal of Medicine reckons with its racist past and complicity in slavery

STAT

The New England Journal of Medicine, the world’s oldest continually published medical journal, publicly reckoned with its history and complicity surrounding slavery and racism Wednesday, publishing the first of a series of essays by independent historians on the role the prestigious publication has played in perpetuating racist thinking in medicine that continues to this day.

145
145
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Experts Say More Research Is Needed to Understand Obesity-Cancer Link

Pharmacy Times

Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.

139
139
article thumbnail

‘Last roll of the dice’ for a near-term HIV vaccine fails

STAT

A study billed as the last chance to develop an HIV vaccine this decade has been shut down, investigators announced Wednesday at a conference in Harare, Zimbabwe. The trial, known as PrEPVacc, was testing two different vaccine regimens on about 1,500 volunteers in East and Southern Africa. After multiple other high-profile trials failed , a PrEPVacc investigator described the study this summer as “ the last roll of the dice ” for an HIV vaccine until the 2030s.

Vaccines 143

More Trending

article thumbnail

FDA endorses Novartis' 'pipeline in a pill,' granting first nod for potential blockbuster Fabhalta

Fierce Pharma

With an FDA approval in PNH, Novartis has gained its first nod for iptacopan, dubbed two months ago “a pipeline in pill," by analysts at ODDO BHF.

FDA 134
article thumbnail

UnitedHealth report: Chronic conditions like depression, diabetes are on the rise

Fierce Healthcare

Chronic conditions, including mental health needs, are on the rise, according to a new report. | The United Health Foundation, the philanthropic arm of industry giant UnitedHealth Group, released its annual America's Health Rankings report.

137
137
article thumbnail

Getting the lead out of the water supply: How one health expert crunched the numbers and prodded the EPA

STAT

It’s known that lead in the water supply has severe health effects, including brain damage in children and heart and liver issues in adults. Now the Environmental Protection Agency has released an ambitious and expensive proposal to replace 100% of the lead pipes in water system service lines across the country over the next 10 years. Ronnie Levin, a former EPA scientist and an environmental health instructor at the Harvard Chan School of Public Health, deems it “ a good move in th

132
132
article thumbnail

A tough 2024 is on the horizon. Here's how Deloitte says healthcare leaders should prepare

Fierce Healthcare

Many of the past year’s buzziest topics and omnipresent struggles will likely rear their heads as major talking points across 2024, per the year-ahead predictions of Deloitte’s healthcare industry | Generative AI, outsourcing and skilled labor retention are among the focal points provider and payer executives will need to keep in their crosshairs.

136
136
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it?

STAT

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales. CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here.

130
130
article thumbnail

Hims & Hers rolls out weight loss program with future plans to include GLP-1 drugs

Fierce Healthcare

Digital health company Hims & Hers launched its much-anticipated weight loss program this week that includes digital tracking tools, educational content and access to medications. | Digital health company Hims & Hers launched its much-anticipated weight loss program this week that includes digital tracking tools, educational content and access to medications.

133
133
article thumbnail

STAT+: Using AI, scientists create blood test that measures organ aging and predicts disease risk

STAT

In today’s mostly plague- and famine-free world, if you can avoid more modern scourges like gun and car violence , you can expect your death to arrive not with a bang but a whimper; when one of your organs sput-sput-sputters out. And it is usually just one organ or organ system. For some, it’s a calcium-clogged heart. For others, kidneys that no longer filter.

128
128
article thumbnail

Cardiovascular disease is a major concern for women. Here's what employers can do

Fierce Healthcare

Cardiovascular disease is a key health concern for women, and a new guide seeks to arm employers with the tools and information need | Cardiovascular disease is a key health concern for women, and a new guide seeks to arm employers with the tools and information needed to help workers manage these needs.

129
129
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Stephen Hemsley, UnitedHealth Group board chair, sells nearly $113 million in stock

STAT

Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold nearly $113 million worth of company stock since the middle of October, new filings show. Hemsley most recently sold $36.4 million worth of stock on Tuesday, according to the documents filed with the Securities and Exchange Commission. The other $76.5 million of UnitedHealth stock was sold in October and November.

article thumbnail

Seattle Children’s Hospital launches BrainChild Bio for CNS therapies

Pharmaceutical Technology

Seattle Children's launched BrainChild Bio to focus on expediting the development of CAR T-cell therapies in central nervous system tumours.

Hospitals 124
article thumbnail

STAT+: Using Pap smears for earlier ovarian cancer detection shows promise in small new study

STAT

Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered. If a tumor is found when it’s small and cancer cells haven’t spread, treatment works well for 90% of patients. But most women are diagnosed at stage 3 or later in their disease, when only 30% reach the five-year survival benchmark.

126
126
article thumbnail

Expert Discusses A Health System Specialty Pharmacy Initiative: Abemaciclib Linkage to Care

Pharmacy Times

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 billion. The deal marks the second billion-dollar acquisition by AbbVie in under a week. Facing the prospect of declining sales from two of its best-selling drugs, the company also acquired Immunogen and its ovarian cancer treatment for $10 billion last Thursday.

124
124
article thumbnail

Advocacy and Precision in Hemophilia Pharmacy Care: Insights and Best Practices

Pharmacy Times

Experts discuss the critical role of specialty pharmacists in advocating for patients during challenging moments in their hemophilia treatment journey and explore precision dosing considerations and the importance of adherence to dosing guidelines.

123
123
article thumbnail

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

Fierce Pharma

After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. | In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. Many years later, Novartis is settling the case.

123
123
article thumbnail

Enhancing Hemophilia Care: The Role of Specialty Pharmacies and Coordinated Efforts

Pharmacy Times

Atta Chowdhry, RPh, and Lisa Schrade, PharmD, discuss best practices in coordinating specialty pharmacy services between payers and prescribers to ensure timely access to critical hemophilia treatments.

article thumbnail

CalOptima launches campaign delivering free naloxone, a first-of-its-kind accomplishment for a public health plan

Fierce Healthcare

Attempting to reduce the number of drug overdose deaths in Orange County, California, CalOptima Health is beginning a $15 million campaign to distribute free naloxone to members. | CalOptima became the first public health plan to distribute free naloxone to members, the company recently announced.

121
121
article thumbnail

Artificial Intelligence Changing the Landscape for Healthcare Social Media Marketing

PharmExec

Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.

119
119
article thumbnail

Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents

STAT

With 10 days to go, only one company has responded to a demand by the U.S. Federal Trade Commission for several brand-name drugmakers to delist dozens of patents that were improperly or inaccurately listed in a government registry, according to a source familiar with the matter. As a result, the agency is readying plans to file lawsuits against the other companies, some of which are among the biggest drugmakers in the world, such as AbbVie, AstraZeneca, and GSK.

118
118
article thumbnail

The Oxford R21 malaria vaccine and the imperative of continued malaria testing

pharmaphorum

The Oxford R21 malaria vaccine and the imperative of continued malaria testing Mike.

Vaccines 116
article thumbnail

STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues

STAT

In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily halt a controversial law that is designed to provide transparency into prescription drug pricing over concerns that it is unconstitutional. The order was issued in response to a lawsuit filed last July by the Association for Accessible Medicine, which argued the law gives Minnesota the power to regulate interstate commerce and apply the law to prices charged in other states.

117
117
article thumbnail

Daiichi Sankyo unit claims $182m in Novartis patent dispute

pharmaphorum

Daiichi Sankyo unit claims $182m in Novartis patent dispute Phil.

116
116
article thumbnail

Opinion: STAT+: A bold approach to pay for weight loss drugs for everyone who needs them

STAT

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Insurance 114
article thumbnail

Protecting the immunocompromised: Preventative measures against COVID-19

pharmaphorum

Protecting the immunocompromised: Preventative measures against COVID-19 Mike.

116
116
article thumbnail

Education Around Importance of Medication Monitoring Procedures Key at a Long-Term Care Psychiatric Facility

Drug Topics

Increased clinical awareness around the value of lithium monitoring was ultimately achieved.

112
112
article thumbnail

SABCS: Handing Novartis a win, Lilly's Verzenio barely misses overall survival goal in first-line breast cancer

Fierce Pharma

Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. | Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial.

111
111
article thumbnail

Why Safety is Crucial in Hazardous Drug Compounding

Drug Topics

A Q&A with Lisa McCabe, PharmD, MBA, BSN, director of Health System Pharmacy at Cardinal Health.